Source avec lien : Indoor Air, 32(10). 10.1111/ina.13118
Le SRAS-CoV-2 a été détecté à la fois dans l’air et sur les surfaces, mais des questions subsistent quant aux facteurs environnementaux et spécifiques aux patients qui affectent la transmission du virus. En outre, des informations plus détaillées sur l’échantillonnage viral de l’air sont nécessaires. Cette étude de cohorte prospective présente les résultats d’échantillons d’air et de surface prélevés dans l’environnement de patients hospitalisés et de patients indexés COVID-19 traités à domicile et compare les résultats entre les environnements mesurés et les facteurs liés aux patients.
Abstract SARS-CoV-2 has been detected both in air and on surfaces, but questions remain about the patient-specific and environmental factors affecting virus transmission. Additionally, more detailed information on viral sampling of the air is needed. This prospective cohort study (N =?56) presents results from 258 air and 252 surface samples from the surroundings of 23 hospitalized and eight home-treated COVID-19 index patients between July 2020 and March 2021 and compares the results between the measured environments and patient factors. Additionally, epidemiological and experimental investigations were performed. The proportions of qRT-PCR-positive air (10.7% hospital/17.6% homes) and surface samples (8.8%/12.9%) showed statistical similarity in hospital and homes. Significant SARS-CoV-2 air contamination was observed in a large (655.25?m3) mechanically ventilated (1.67 air changes per hour, 32.4?421?L/s/patient) patient hall even with only two patients present. All positive air samples were obtained in the absence of aerosol-generating procedures. In four cases, positive environmental samples were detected after the patients had developed a neutralizing IgG response. SARS-CoV-2 RNA was detected in the following particle sizes: 0.65?4.7 ?m, 7.0?12.0 ?m, >10 ?m, and <100??m. Appropriate infection control against airborne and surface transmission routes is needed in both environments, even after antibody production has begun. Lisez l’article